Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PLK1 | P53350 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 9/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12680148 | 0.92 | PLK1 (0.49) | MAPTPLK1FAAHACHEACACB | |
| SCHEMBL12418675 | 0.84 | ALDH1A1 (0.44) | MAPTPLK1RAB9AFAAHACHE | |
| SCHEMBL9327664 | 0.84 | PLK1 (0.65) | PLK1FAAH | |
| SCHEMBL12414160 | 0.84 | GAA (0.49) | MAPTPLK1FAAHACHEALDH1A1 | |
| SCHEMBL14753644 | 0.81 | FAAH (0.49) | PLK1FAAHACHE | |
| SCHEMBL12893245 | 0.81 | ALDH1A1 (0.51) | MAPTPLK1RAB9AACHEALDH1A1 | |
| SCHEMBL4751488 | 0.81 | PLK1 (0.75) | MAPTPLK1RAB9A | |
| SCHEMBL9326201 | 0.80 | PLK1 (0.62) | MAPTPLK1RAB9AFAAHALDH1A1 | |
| SCHEMBL26698250 | 0.80 | LMNA (0.53) | MAPTRAB9AACACBALDH1A1 | |
| SCHEMBL9326191 | 0.77 | SMN1; SMN2 (0.59) | PLK1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110171162-A1 | POLYMER CONJUGATES OF THYMOSIN ALPHA 1 PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171162-A1 | POLYMER CONJUGATES OF THYMOSIN ALPHA 1 PEPTIDES | TMSB4X, TMSB10, TAP1 | MAPT 837/4885PLK1 2245/4885RAB9A 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.